Posted inNews Sexual Health
Rising syphilis rates in West Midlands cause concern
New data from the UK Health Security Agency, published last Friday, shows a steep increase…
Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inInternational News PrEP Prevention
Concern as PrEP supplies run low in Australia
Australian sexual health and HIV organisations are sending out reminders for PrEP users to "plan…
Posted inHealthcare International News PrEP Prevention
PrEP approved to prevent HIV in Japan
Japan has approved the use of Truvada (TDF/FTC), sold by Gilead Sciences under the brand name Truvada, as PrEP for the prevention of HIV in the country.
Posted inInternational News Sexual Health
New virulent MPOX strain emerges: Latest info from UK organisations
Following the death of 524 people in the Democratic Republic of Congo The World Health…
Posted inNews PrEP Prevention
UK’s first Digital PrEP service starts in East Sussex
A new digital PrEP service has just launched in East Sussex, making it easier for…
Posted inConferences News Research Treatment
HIV viral rebounds following CRISPR gene therapy
EBT-101, a gene-editing therapy utilising CRISPR technology, showed promising safety and tolerability in an initial…